Sexual dysfunction adverse event reports that record this term

Kind of term: MedDRA preferred term
Plain meaning: a sexual problem

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 11,406 adverse event reports that record the MedDRA preferred term Sexual dysfunction. In plain words, the term means: a sexual problem. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 697 reports in the 12 months to June 2026 and 955 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 805 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 697 (0.1%) record this term. Reports for male patients were 69.1% of the reports that record this term and 34.6% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Plain meaning

A sexual problem. The words are from the fixed dictionary of this site. They add nothing to a report.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 120 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Sexual dysfunction name as a suspect product, in order of name
Drug	Class	Reports with this term
Abilify	Atypical antipsychotic	643
Abilify Maintena		322
Acetaminophen Oxycodone Hydrochloride		53
Amisulpride	Dopamine-2 receptor antagonist	29
Ampyra	Potassium channel blocker	31
Androgel		25
Aripiprazole	Atypical antipsychotic	570
Asenapine maleate	Atypical antipsychotic	31
Atorvastatin		28
Aubagio	Pyrimidine synthesis inhibitor	69
Avodart		70
Brintellix		41
Bupropion	Aminoketone	56
Bupropion hydrochloride	Aminoketone	101
Butrans	Partial opioid agonist	28
Celexa	Serotonin reuptake inhibitor	31
Chantix	Partial cholinergic nicotinic agonist	26
Cipralex		34
Ciprofloxacin	Fluoroquinolone antibacterial	34
Citalopram	Serotonin reuptake inhibitor	278
Citalopram hydrobromide	Serotonin reuptake inhibitor	49
Clonazepam	Benzodiazepine	47
Clozapine	Atypical antipsychotic	427
Clozaril	Atypical antipsychotic	109
Cosentyx	Interleukin-17A antagonist	61
Crestor	HMG-CoA reductase inhibitor	34
Cymbalta		261
Desvenlafaxine succinate	Serotonin and norepinephrine reuptake inhibitor	62
Dilaudid	Opioid agonist	71
Duloxetine	Serotonin and norepinephrine reuptake inhibitor	54
Duloxetine hydrochloride	Serotonin and norepinephrine reuptake inhibitor	34
Effexor	Serotonin and norepinephrine reuptake inhibitor	50
Enbrel	Tumor necrosis factor blocker	33
Escitalopram	Serotonin reuptake inhibitor	295
Escitalopram oxalate	Serotonin reuptake inhibitor	46
Finasteride	5-alpha reductase inhibitor	983
Flomax		37
Fluoxetine	Serotonin reuptake inhibitor	169
Flupentixol		271
Flupentixol Decanoate		187
Flupentixol Dihydrochloride		177
Gabapentin	Anti-epileptic agent	74
Geodon	Atypical antipsychotic	27
Gilenya	Sphingosine 1-phosphate receptor modulator	47
Haldol		36
Haloperidol	Typical antipsychotic	55
Humira		51
Hydrocodone bitartrate and acetaminophen	Opioid agonist	113
Invega	Atypical antipsychotic	271
Invega Sustenna	Atypical antipsychotic	169
Lamictal	Anti-epileptic agent	53
Lamotrigine	Anti-epileptic agent	30
Latuda	Atypical antipsychotic	449
Levetiracetam		35
Lexapro	Serotonin reuptake inhibitor	131
Lipitor	HMG-CoA reductase inhibitor	25
Lithium	Mood stabilizer	40
Lurasidone hydrochloride	Atypical antipsychotic	139
Lyrica		92
Methotrexate	Folate analog metabolic inhibitor	43
Minoxidil	Arteriolar vasodilator	88
Mirena	Progestin	64
Mirtazapine		113
Morphine sulfate	Opioid agonist	96
MS Contin	Opioid agonist	69
Neurontin		28
Olanzapine	Atypical antipsychotic	501
Orgovyx	Gonadotropin releasing hormone receptor antagonist	43
Oxycodone and acetaminophen	Opioid agonist	68
Oxycodone hydrochloride	Opioid agonist	212
OxyContin	Opioid agonist	210
Paliperidone	Atypical antipsychotic	326
Paliperidone palmitate	Atypical antipsychotic	204
ParaGard T 380A	Copper-containing intrauterine device	253
Paroxetine	Serotonin reuptake inhibitor	92
Paroxetine hydrochloride	Serotonin reuptake inhibitor	65
Paxil	Serotonin reuptake inhibitor	293
Percocet	Opioid agonist	55
Pregabalin		59
Propecia	5-alpha reductase inhibitor	1,718
Proscar	5-alpha reductase inhibitor	299
Prozac	Serotonin reuptake inhibitor	158
Quetiapine	Atypical antipsychotic	238
Quetiapine fumarate	Atypical antipsychotic	458
Revlimid	Thalidomide analog	36
Rexulti	Atypical antipsychotic	27
Risperdal	Atypical antipsychotic	291
Risperdal Consta		195
Risperidone	Atypical antipsychotic	573
Rotigotine	Nonergot dopamine agonist	28
Saphris	Atypical antipsychotic	402
Seroquel	Atypical antipsychotic	119
Sertraline	Serotonin reuptake inhibitor	455
Sertraline hydrochloride	Serotonin reuptake inhibitor	66
Simvastatin	HMG-CoA reductase inhibitor	43
Strattera	Norepinephrine reuptake inhibitor	99
Tamsulosin		31
Tramadol		59
Trazodone		30
Trintellix		111
Tysabri	Integrin receptor antagonist	37
Venlafaxine	Serotonin and norepinephrine reuptake inhibitor	168
Venlafaxine hcl	Serotonin and norepinephrine reuptake inhibitor	25
Venlafaxine hydrochloride	Serotonin and norepinephrine reuptake inhibitor	94
Viagra	Phosphodiesterase 5 inhibitor	49
Vicodin		28
Viibryd		48
Vioxx		45
Vivitrol		32
Vortioxetine		41
Wellbutrin	Aminoketone	45
Zeldox		44
Ziprasidone	Atypical antipsychotic	114
Ziprasidone hydrochloride	Atypical antipsychotic	373
Zoloft	Serotonin reuptake inhibitor	203
Zuclopenthixol		208
Zuclopenthixol Acetate		281
Zuclopenthixol Decanoate		254
Zuclopenthixol Hydrochloride		118
Zyprexa	Atypical antipsychotic	579

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 38 pharmacologic classes with 25 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Sexual dysfunction name, in order of name
Class	Reports with this term
5-alpha reductase inhibitor	3,007
alpha-Adrenergic blocker	32
Aminoketone	228
Angiotensin 2 receptor blocker	36
Anti-epileptic agent	183
Arteriolar vasodilator	88
Atypical antipsychotic	7,085
Benzodiazepine	135
beta-Adrenergic blocker	54
Central nervous system stimulant	85
Copper-containing intrauterine device	253
Dopamine-2 receptor antagonist	34
Fluoroquinolone antibacterial	60
Folate analog metabolic inhibitor	46
Gonadotropin releasing hormone receptor antagonist	45
HMG-CoA reductase inhibitor	111
Integrin receptor antagonist	37
Interferon beta	28
Interleukin-17A antagonist	61
Mood stabilizer	58
Nonergot dopamine agonist	32
Nonsteroidal anti-inflammatory drug	41
Norepinephrine reuptake inhibitor	112
Opioid agonist	1,070
Opioid antagonist	25
Partial cholinergic nicotinic agonist	26
Partial opioid agonist	42
Phosphodiesterase 5 inhibitor	73
Potassium channel blocker	33
Progestin	79
Pyrimidine synthesis inhibitor	73
Retinoid	31
Serotonin and norepinephrine reuptake inhibitor	512
Serotonin reuptake inhibitor	2,377
Sphingosine 1-phosphate receptor modulator	47
Thalidomide analog	43
Tumor necrosis factor blocker	35
Typical antipsychotic	65

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Sexual dysfunction, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Sexual dysfunction
Age	Reports	Share
Under 2	0	0%
2 to 11	11	0.1%
12 to 17	81	0.7%
18 to 44	3,694	32.4%
45 to 64	1,758	15.4%
65 to 74	344	3%
75 and over	118	1%
Age not given	5,400	47.3%

Sex of the patient in the reports that record Sexual dysfunction
Sex	Reports	Share
Female	2,687	23.6%
Male	7,882	69.1%
Unknown or not given	837	7.3%

Age and sex are as the report gives them. 63.2% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Sexual dysfunction: adverse event reports that record this term. https://reportedreactions.com/reaction/sexual-dysfunction/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Sexual dysfunction mean in an adverse event report?

In plain words: a sexual problem. It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page